Drug intelligence / Profile preview

Dolomec

Development stage: Unknown
Lead developer: McW Healthcare
Modality: Small Molecules
Administration: Oral

Overview

**Dolomec** is a marketed oral fixed-dose analgesic and antipyretic combination from McW Healthcare containing ibuprofen 400 mg, methionine 50 mg, and paracetamol 500 mg per tablet. It is used for pain, inflammation, and fever, including musculoskeletal pain and inflammatory arthritic conditions. Ibuprofen provides nonsteroidal anti-inflammatory activity through inhibition of prostaglandin synthesis, while paracetamol contributes analgesic and antipyretic effects; methionine is an amino-acid component of the formulation. ([1mg.com](https://www.1mg.com/drugs/dolomec-tablet-278679))

Brand names: Dolomec
Other names: ibuprofen + methionine + paracetamol

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Dolomec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dolomec.

Explore the full profile